Looking At Madrigal Pharmaceuticals's Recent Unusual Options Activity

Deep-pocketed investors have adopted a bearish approach towards Madrigal Pharmaceuticals MDGL, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MDGL usually suggests something big is about to happen.

We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Madrigal Pharmaceuticals. This level of activity is out of the ordinary.

The general mood among these heavyweight investors is divided, with 22% leaning bullish and 77% bearish. Among these notable options, 6 are puts, totaling $1,298,000, and 3 are calls, amounting to $127,540.

Today's Best Finance Deals

What's The Price Target?

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $170.0 to $260.0 for Madrigal Pharmaceuticals over the last 3 months.

Volume & Open Interest Trends

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Madrigal Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Madrigal Pharmaceuticals's significant trades, within a strike price range of $170.0 to $260.0, over the past month.

Madrigal Pharmaceuticals Option Activity Analysis: Last 30 Days

Largest Options Trades Observed:

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

After a thorough review of the options trading surrounding Madrigal Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.

Present Market Standing of Madrigal Pharmaceuticals

• With a trading volume of 198,618, the price of MDGL is down by -1.0%, reaching $220.0.
• Current RSI values indicate that the stock is may be approaching overbought.
• Next earnings report is scheduled for 14 days from now.

Expert Opinions on Madrigal Pharmaceuticals

In the last month, 1 experts released ratings on this stock with an average target price of $336.0.

• Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Madrigal Pharmaceuticals with a target price of $336.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Madrigal Pharmaceuticals options trades with real-time alerts from Benzinga Pro.